Question Bank › Center of attention has moved to the newest work

Center of attention has moved to the newest working thing

Center of attention has moved to the newest working thing: management's energy is disproportionately on a small but alre

Calls Tested
488
Answered YES
37
Hit Rate
7.6%
rare by design

Kamada Ltd. (KMDA) — this company's answers

NO on the Q2 2023 call 2023-08-16 B+
The model's full reasoning — Q2 2023 call → NOWe need to determine if management devotes a clearly disproportionate share of energy, enthusiasm, and detail to one identifiable part of the business that is still a minority of overall results today, and that part is described as already producing real, current business. The favored part should be presented as the main driver of the company's future. Let's analyze the transcript. The call covers Kamada Ltd. Key products: KEDRAB (anti-rabies immunoglobulin) sold to Kedrion for U.S. distribution, the portfolio of four FDA-approved hyperimmunoglobulins (CYTOGAM, HEPAGAMB, VARIZIG, WINRHO), and the Israeli distribution business. Also, there is a development pipeline: Inhaled Alpha-1 Antitrypsin (InnovAATe trial) for Alpha-1 Deficiency, and plasma collection centers. Management discusses financial results, reiterates guidance. They talk about KEDRAB sales increase, the extension of distribution agreement with Kedrion through 2026, and active discussions to expand collaboration. They mention the U.S. team promoting specialty immunoglobulins (CYTOGAM, VARIZIG). They also mention the FDA approval for manufacturing CYTOGAM at their Israeli facility, and Health Canada approval. They talk about Kamada Plasma (plasma collection) with a center in Beaumont, Texas, and opening a second in Houston in early 2024. They discuss the InnovAATe trial enrollment (62 patients, ~30% of target), positive EMA advice, and plans to discuss with FDA. Now, which part gets the most attention? The call seems to cover multiple aspects. However, the CEO's opening remarks highlight KEDRAB sales increase, the portfolio of FDA-approved products, and the Israeli distribution business. They also mention the FIMI investment. Then they go into KEDRAB details, then the specialty portfolio, then CYTOGAM manufacturing, then plasma collection, then InnovAATe. The InnovAATe is a development program, not yet generating revenue. The plasma collection is also early stage. The main revenue drivers are KEDRAB and the IgG portfolio. KEDRAB is a significant part of revenue? In 2022, KEDRAB revenue was $16 million. Total revenue for 2022? The guidance for 2023 is $138-146 million. So KEDRAB is a minority. The IgG portfolio (acquired in late 2021) is also a growth driver.

← Back to the full KMDA analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management devote a clearly DISPROPORTIONATE share of its energy, enthusiasm, and detail to ONE identifiable part of the business that is still a MINORITY of the company's overall results today — and is that favored part described as ALREADY PRODUCING real, current business (actual revenue, orders, customers, volumes, openings, bookings, or deployments happening now), with management treating it as the main thing that will drive where the company goes from here? Answer YES when the transcript conveys, in whatever form fits the business, ONE coherent pattern: there is a specific, nameable piece of the company — a product line, service, brand, program, technology, customer segment, geography, format, or business unit — that is plainly smaller today than the company's established base, yet it receives the richest discussion on the call: management returns to it repeatedly, volunteers specifics about it (its recent wins, its pace, its economics, its next steps), speaks about it with visibly more conviction than about the rest of the business, and frames the company's future primarily around it. At the same time, that favored piece must be described as genuinely working NOW — real paying activity in the recent period that management points to — not merely a promising initiative, pipeline, or plan. The rest of the business may be healthy, flat, or struggling; what matters is the contrast: the established majority of the company gets routine treatment while the small working piece gets the spotlight and is presented as the company's trajectory. Answer NO if management's attention is spread evenly across the business, or the call is a routine tour of segments with no single favored piece. NO if the piece receiving the spotlight is already the company's main business or the majority of its results. NO if the favored piece is still pre-revenue, aspirational, in pilot with nothing yet sold, or described mainly through plans, potential, or market size rather than current paying activity. NO if the spotlight simply reflects a one-time event this quarter (an acquisition just closed, a single large deal, an asset sale) rather than an ongoing driver management is building around. NO if management gives the newer piece only brief or passing mention, however positive. NO if the emphasis appears only in analysts' questions and management does not itself carry the enthusiasm in its own remarks. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
HCKT The Hackett Group, Inc. Q1 2024 2024-05-08 C
AES The AES Corporation Q1 2024 2024-05-03 C+
LTRX Lantronix, Inc. Q3 2024 2024-04-29 C
HUYA HUYA Inc. Q4 2023 2024-03-19 C
NICE NICE Ltd. Q4 2023 2024-02-22 B+
PUMP ProPetro Holding Corp. Q4 2023 2024-02-21 C+
APAM Artisan Partners Asset Management Inc. Q3 2023 2023-11-01 C+
ANGO AngioDynamics, Inc. Q1 2024 2023-10-04 B
BZUN Baozun Inc. Q2 2023 2023-08-28 D
APPS Digital Turbine, Inc. Q1 2024 2023-08-08 D
CALX Calix, Inc. Q1 2023 2023-04-20 C+
DKS DICK'S Sporting Goods, Inc. Q4 2022 2023-03-07 B
BLZE Backblaze, Inc. Q3 2022 2022-11-11 D
PKX POSCO Holdings Inc. Q3 2022 2022-10-24 D
YMM Full Truck Alliance Co. Ltd. Q2 2022 2022-08-25 C+
MGNI Magnite, Inc. Q1 2022 2022-05-04 D
ZENV Zenvia Inc. Q4 2021 2022-03-17 C+
KD Kyndryl Holdings, Inc. Q4 2021 2022-03-01 C+
SLQT SelectQuote, Inc. Q2 2022 2022-02-07 F
ZH Zhihu Inc. Q3 2021 2021-11-22 D
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
LPTH LightPath Technologies, Inc. Q4 2021 2021-09-09 D
ASAN Asana, Inc. Q2 2022 2021-09-01 B+
UFI Unifi, Inc. Q4 2021 2021-08-07 B
ADSK Autodesk, Inc. Q3 2019 2018-11-20 A
LRN Stride, Inc. Q1 2019 2018-10-23 B
IRT Independence Realty Trust, Inc. Q2 2018 2018-08-02 B
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
FOSL Fossil Group, Inc. Q1 2018 2018-05-08 C
INST Instructure's Q4 2017 2018-02-12 B+
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
MITK Mitek Systems, Inc. Q4 2017 2017-11-07 C+
GNTX Gentex Corporation Q3 2017 2017-10-20 B
PTC PTC Inc. Q3 2017 2017-07-19 C+
NWSA News Corporation Q2 2016 2016-08-08 C+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+
WK Workiva Inc. Q4 2015 2016-03-01 B

How the model reasoned

YMM · Q2 2022 → YESThe question is: Does management devote a clearly DISPROPORTIONATE share of its energy, enthusiasm, and detail to ONE identifiable part of the business that is still a MINORITY of the company's overal...YES The transcript shows management devoting a clear, extended spotlight to the commission/online transaction service (20%+ of revenue, minority share). They repeatedly highlight its strong performance, dynamic adjustments, user retention metrics, and role in driving monetization and future growth, framing it as a key driver for the company's trajectory while 347.8 million in commissions is already generating real revenue now. Other areas like overall GTV, fulfillment rates, and user MAUs receive routine coverage, but the commission piece gets the richest, most conviction-driven discussion.
PUMP · Q4 2023 → YESThe question is: Does management devote a clearly DISPROPORTIONATE share of its energy, enthusiasm, and detail to ONE identifiable part of the business that is still a MINORITY of the company's overal...YES The transcript shows management devoting a clearly disproportionate share of its prepared remarks and Q&A to the FORCE electric fleet offering (a new technology/service line). They describe it as minority today (only two fleets operating out of 14-15 active, with plans for three and four more), yet repeatedly highlight its real 2023 performance (on contract, strong results, efficient performance, customer satisfaction, diesel displacement), its unique positioning, and its role as the core driver of the company's future trajectory through fleet transition and industrialization.
NICE · Q4 2023 → YESThe question is: Does management devote a clearly DISPROPORTIONATE share of its energy, enthusiasm, and detail to ONE identifiable part of the business that is still a MINORITY of the company's overal...YES The transcript shows management devoting a clearly disproportionate share of its energy, enthusiasm, and detail to AI (Enlighten AI, Copilot, Autopilot) as the catalyst driving growth across CXone, digital engagement, platformization, and new solutions. This is framed as the overarching theme that will shape the 2024 trajectory and beyond. AI is described as already producing real, current business activity: 375% increase in Enlighten bookings in Q4, multiple seven-digit ACV deals won with AI features, and accelerating adoption among customers and prospects.

More from the question bank

Selling into a customer's own emergencyStale terms, scheduled resetAnalysts still asking about the old story whManagement is playing referee between competDemand off the charts · scarcity_amplificatiLeaning into the stormAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.